Top 5 Casino Stocks To Buy Right Now


You can bet on it: Sports gambling is about to expand, big time, in the United States.

Right now, the only place you can legally bet on sports is Nevada.

But on Monday, the Supreme Court struck down a federal law that prohibited legalized sports gambling anywhere but Nevada.

So what does this court decision mean, exactly?

Now that there is no longer a federal law against sports gambling, each state is free to pass laws that govern where people will be able to bet on sports and how.


“It’ll be a state-by-state matter,” said Eugene Christiansen, an expert on casino gambling and consultant to the industry. “I’m sure there will be a wide variety as to how fast or how slow the licensing proceeds.”

Are any other states close to approving sports betting?

Six states, including New Jersey which that brought the lawsuit to the Supreme Court, have already passed laws to allow casinos to take sports bets once the federal law was struck down, according to Geoff Freeman, CEO of the American Gaming Association. Those states are New Jersey, New York, West Virginia, Mississippi, Pennsylvania and Connecticut.

Top 5 Casino Stocks To Buy Right Now: Cimpress N.V(CMPR)


Advisors’ Opinion:

  • [By Steve Symington]

    Cimpress NV(NASDAQ:CMPR)announced fiscal third-quarter 2018 results on Wednesday after the market closed, detailing the continued fruits of last year’s Vistaprint restructuring and steady growth at each of its three core business segments.Still, shares of the mass customization specialist were down on Thursday in response to the news.

  • [By Logan Wallace]

    SunTrust Banks reaffirmed their hold rating on shares of Cimpress (NASDAQ:CMPR) in a research note published on Tuesday. SunTrust Banks currently has a $144.00 price objective on the business services provider’s stock.

  • [By Joseph Griffin]

    Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

    Get Cimpress alerts:

    Cimpress (CMPR) Earns Hold Rating from SunTrust Banks (americanbankingnews.com) Katryn Blake Sells 9,297 Shares of Cimpress (CMPR) Stock (americanbankingnews.com) Insider Selling: Cimpress (CMPR) CEO Sells 4,648 Shares of Stock (americanbankingnews.com) Cimpress’ (CMPR) “Sell” Rating Reiterated at Aegis (americanbankingnews.com) Cimpress (CMPR) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)


    A number of equities analysts recently weighed in on the company. SunTrust Banks reaffirmed a “hold” rating and issued a $144.00 price target on shares of Cimpress in a report on Tuesday. ValuEngine raised Cimpress from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Aegis reaffirmed a “sell” rating and issued a $114.00 price target on shares of Cimpress in a report on Tuesday. BidaskClub cut Cimpress from a “buy” rating to a “hold” rating in a report on Friday, May 4th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $165.00 price target on shares of Cimpress in a report on Tuesday, May 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $140.00.

Top 5 Casino Stocks To Buy Right Now: Xplore Technologies Corp(XPLR)


Advisors’ Opinion:

  • [By Logan Wallace]

    A10 Networks (NYSE: ATEN) and Xplore Technologies (NASDAQ:XPLR) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

  • [By Logan Wallace]

    Xplore Technologies (NASDAQ: XPLR) is one of 25 publicly-traded companies in the “Computer & office equipment” industry, but how does it compare to its peers? We will compare Xplore Technologies to related businesses based on the strength of its dividends, profitability, earnings, risk, valuation, analyst recommendations and institutional ownership.

Top 5 Casino Stocks To Buy Right Now: Gilead Sciences, Inc.(GILD)


Advisors’ Opinion:

  • [By George Budwell]

    When it comes to biotech stocks, Celgene(NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) are easily two of the brightest stars. After all, these two top dogs have generated enormous returns for investors since the start of the biotech bull market back in 2010:

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD), Micron Technology (NASDAQ:MU), and Walker & Dunlop (NYSE:WD) actually have relatively low valuations. Here’s why these are three bargain stocks you can buy right now.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Gilead Sciences, Inc. (NASDAQ: GILD) which rose about 4% to $88.78. The stocks 52-week range is $63.76 to $89.54. Volume was roughly 18 million compared to the daily average volume of about 8 million.

Top 5 Casino Stocks To Buy Right Now: The Blackstone Group L.P.(BX)

Advisors’ Opinion:

  • [By ]

    The market hasn’t had its needed purge yet says Byron Wien, who is Vice Chairman in the Private Wealth Solutions of Blackstone Group (BX) . “We will retest the February lows [in the markets],” Wien, 86, said on a call Thursday with media. Wien continues to believe the S&P 500 will rally back after testing the lows, charting a path to 3,000 by year end.

  • [By Jordan Wathen]

    Shares ofGramercy Property Trust (NYSE:GPT) had soared by more than 15% as of 12:03 p.m. EDT Monday on news that the real estate investment trust will be acquired byBlackstone Group’s(NYSE:BX) Blackstone Real Estate Partners VIII L.P fund in an all-cash transaction.

  • [By Lisa Levin]

    Gramercy Property Trust (NYSE: GPT) shares were also up, gaining 16 percent to $27.51 after the company agreed to be acquired by Blackstone Group L.P. (NYSE: BX) for $27.50 per share.

Top 5 Casino Stocks To Buy Right Now: Endocyte, Inc.(ECYT)


Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Endocyte (ECYT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Endocyte (NASDAQ:ECYT) is set to release its earnings data after the market closes on Monday, May 7th. Analysts expect Endocyte to post earnings of ($0.19) per share for the quarter.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Endocyte (ECYT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Exploding biotech names are nothing new to this bull market. You might recall the headline swirling around Endocyte Inc. (NASDAQ:ECYT) as it posted one-day gains of more than 150% during the fourth quarter. The triple-digit move was sparked by a licensing agreement for the firms phase 3 prostate cancer drug. Now, these moves are becoming almost commonplace.

Leave a Reply

Your email address will not be published. Required fields are marked *